« Back
Liposomes and Nanoparticles as Delivery Vehicles for the Treatment of Lung Diseases
Poster Title: Liposomes and Nanoparticles as Delivery Vehicles for the Treatment of Lung Diseases
Submitted on 06 Oct 2014
Author(s): Raisa Kiseleva1, Jennifer Mulligan2, Carl Atkinson2, Rodney Schlossser2, Alexey Vertegel1
Affiliations: 1Clemson University, Clemson, SC, 2Ralph H. Johnson VA Medical Center, Charleston, SC
Poster Views: 6,646
View poster »

Poster Information
Abstract: Reactive oxygen species (ROS) are greatly involved in important physiological and pathophysiological processes. Overproduction of most toxic ROS - superoxide radicals - leads to a variety of detrimental health conditions including cardiovascular disease, neurodegenerative disorders, and extensive oxidative inflammation. Among others, lung tissue is especially susceptible to oxidative insult because it is in direct contact with oxygen from the air. Inhaled toxic agents such as dust or smoke could stimulate the generation of ROS, which in turn provokes chronic inflammation and development of chronic obstructive pulmonary disease (COPD). To combat these unrelenting conditions, lung tissue is protected by a variety of antioxidant mechanisms. Superoxide dismutases (SOD) are a group of antioxidant enzymes responsible for conversion of superoxide radicals to much less reactive hydrogen peroxide. We propose their use to alleviate lung conditions such as COPD. Major obstacle in drug delivery to the lung is rapid clearance of the drug by respiratory epithelium. To overcome these limitations we propose using delivery vehicles such as liposomes and polymeric nanoparticles
Normal human bronchial epithelial (NHBE) cell culture was used as cell culture model in In vitro study of targeting effect. These nanoparticulate systems have shown to have better targeting in comparison to the plain NPs and samples with control antibodies. Nanoparticles were also loaded with antioxidative drugs (SOD/SOD mimic) to show the protective efficacy against ROS damaging production.
Summary: Targeted nanoparticle-based drug delivery to the lungs is an emerging area of interest for both scientists and medical workers because it allows better drug retention in the lungs and can provide prolonged drug release. In our study we investigated the potential of using liposomes and polymeric nanoparticles surface modified with a specific antibody as drug carriers for targeted drug delivery to the lungs.References: Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Troubleshooting and Things You Must Know About Quantum Dots
Richard J. Gray

Biodegradation of Natural Rubber Derivative by Fungi.
Osama alam

Different Cell Separation Strategies
Richard J. Gray

Abstract 23: Precision medicine approaches to Fanconi anemia oral cancer personalized prevention and treatment
Daniel K. Swenson; Beverly R. Wuertz; Mustafa M. Ali; Gretchen M. Unger; Frank G. Ondrey

Praziquantel lipid nanocapsules: An oral nanotherapeutic for potential schistosoma mansoni targeting
Rokaya O Amara,1,2 Alyaa A Ramadan,1 Riham M El-Moslemany,1 Maha M Eissa,3 Mervat Z El-Azzouni,3 and Labiba K El-Khordagui1